Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) shot up 7.2% during trading on Friday . The stock traded as high as $2.41 and last traded at $2.39. 3,367,051 shares traded hands during trading, an increase of 255% from the average session volume of 948,393 shares. The stock had previously closed at $2.23.

Several brokerages have commented on CPRX. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 9th. Piper Jaffray Companies began coverage on shares of Catalyst Pharmaceuticals in a research report on Friday, September 7th. They set an “overweight” rating and a $5.00 price target on the stock. Cantor Fitzgerald set a $8.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, October 3rd. Oppenheimer set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 9th. Finally, BidaskClub raised shares of Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $5.65.

The company has a market capitalization of $236.30 million, a price-to-earnings ratio of -11.38 and a beta of 2.01.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). As a group, sell-side analysts expect that Catalyst Pharmaceuticals Inc will post -0.3 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in shares of Catalyst Pharmaceuticals by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 23,383 shares during the last quarter. Millennium Management LLC increased its stake in shares of Catalyst Pharmaceuticals by 16.5% during the 2nd quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock worth $5,024,000 after purchasing an additional 227,918 shares during the last quarter. GSA Capital Partners LLP increased its stake in shares of Catalyst Pharmaceuticals by 295.7% during the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock worth $1,187,000 after purchasing an additional 284,409 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 12.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 208,404 shares of the biopharmaceutical company’s stock worth $651,000 after purchasing an additional 23,500 shares during the last quarter. Finally, Lido Advisors LLC increased its stake in shares of Catalyst Pharmaceuticals by 46.5% during the 2nd quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 27,766 shares during the last quarter. Institutional investors own 49.61% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/catalyst-pharmaceuticals-cprx-shares-up-7-2/2668782.html.

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Featured Story: Understanding each part of a balance sheet

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.